Discover how medtech companies are leveraging data and hardware to drive AI advancements, improve clinical outcomes, and ...
Rhythm rides strong volume growth, AI-driven innovation and primary care expansion, but reimbursement pressure and rising ...
The updated fair value estimate for iRhythm Holdings is now US$211.43 per share, compared with the prior US$211, reflecting only a very small change in the modelled price target. That modest ...
Data presented at ACC.26 demonstrate a high prevalence of clinically actionable arrhythmias across CKM patient populations using the Zio® ...
RTW Investments acquired 1,181,990 IRTC shares during Q4 2025, with an estimated position value of $210 million based on the 13F reported at quarter-end. The position represents 2.1% of RTW’s 13F ...
iRhythm (Nasdaq: IRTC) + reported Street-beating fourth quarter results, with analysts seeing momentum for its business. Investors, however, appear to have been looking for more. The day after the ...
iRhythm is transitioning from speculative growth to a quality compounder, driven by operating leverage, expanding indications, and international growth. IRTC forecasts 2025 revenue over $740M and 2026 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results